New publications
Chronic urticaria: Researchers identify the most effective and safe treatments
Last reviewed: 27.07.2025
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
An international team of scientists led by researchers from McMaster University has identified the most effective and safe treatments for chronic urticaria (chronic rash and itching), which affects about 1% of the population and can seriously impair quality of life, sleep and productivity.
The study, published July 15, 2025, in the Journal of Allergy and Clinical Immunology, analyzed data from 93 randomized clinical trials involving more than 11,000 people. It is the first large meta-analysis to compare more than 40 treatment options.
The most effective means are recognized as:
- Omalizumab (an injectable antibody drug) and remibrutinib (a new oral drug) were the best at reducing rash, itching, and swelling.
- Dupilumab has also shown efficacy, particularly in reducing the number of lesions.
- Cyclosporine can be effective, but is associated with an increased risk of side effects (kidney toxicity, increased blood pressure).
"This is the first comprehensive analysis of all current treatment options for chronic urticaria, providing patients and physicians with a clear, evidence-based treatment 'menu'," said senior study author Derek Chu.
The results will be used to prepare new international clinical guidelines.